
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/53926/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Molecular Cancer, 2022, 21, 11.	7.9	46
2	Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer. JAMA Oncology, 2022, 8, 242.	3.4	50
3	Case Report: Complete Remission With Antiâ^'PDâ^'1 and Antiâ^'VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma. Frontiers in Oncology, 2022, 12, 809068.	1.3	7
4	Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study Journal of Clinical Oncology, 2022, 40, 3591-3591.	0.8	0
5	Apatinib versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: Post hoc analyses from the REALITY randomized clinical trial Journal of Clinical Oncology, 2022, 40, 6095-6095.	0.8	1
6	Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3027-e3036.	1.8	15
7	Clinical recommendations for perioperative immunotherapyâ€induced adverse events in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1469-1488.	0.8	7
8	Richer fusion network for breast cancer classification based on multimodal data. BMC Medical Informatics and Decision Making, 2021, 21, 134.	1.5	22
9	Fibrinogen–Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy. Cancer Management and Research, 2021, Volume 13, 4169-4180.	0.9	4
10	Decreased expression of ARID1A invasively downregulates the expression of ribosomal proteins in hepatocellular carcinoma. Biomarkers in Medicine, 2021, 15, 497-508.	0.6	1
11	Abstract 2739: ARID1A deficiency in HBV related hepatocarcinoma patients is associated with upregulated immune activity. , 2021, , .		0
12	Pharmacovigilance Bibliometrics: Visualizing Thematic Development in the Category of Pharmacology and Pharmacy in Web of Science. Frontiers in Pharmacology, 2021, 12, 731757.	1.6	13
13	Prognostic nomograms for patients undergoing radical operation for stage I-III appendiceal adenocarcinoma: A surveillance, epidemiology, and end results database analysis. Journal of Cancer Research and Therapeutics, 2021, 17, 1656.	0.3	3
14	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	1.4	8
15	Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 607-614.	0.6	14
16	Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients. Clinica Chimica Acta, 2020, 510, 88-96.	0.5	4
17	Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer. BMC Medical Genomics, 2020, 13, 7.	0.7	32
18	Common and distinct features of potentially predictive biomarkers in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung by systematic and integrated analysis. Molecular Genetics & Genomic Medicine, 2020, 8, e1126.	0.6	3

#	Article	IF	CITATIONS
19	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	4.2	427
20	The effect of a coix seed oil injection on cancer pain relief. Supportive Care in Cancer, 2019, 27, 461-465.	1.0	30
21	Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first‑line therapy in patients with extensive‑stage small cell lung cancer. Oncology Letters, 2019, 17, 4701-4709.	0.8	6
22	A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study. Journal of Infection and Public Health, 2019, 12, 789-793.	1.9	11
23	Clinical Characteristics and Prognosis of Gastrointestinal Metastases in Solid Tumor Patients: A Retrospective Study and Review of Literatures. Analytical Cellular Pathology, 2019, 2019, 1-7.	0.7	6
24	Deployment and integration of a cognitive technology in China: Experiences and lessons learned Journal of Clinical Oncology, 2019, 37, 6538-6538.	0.8	3
25	Reasons for discordance in treatment approaches between oncology practice and clinical decision support in China Journal of Clinical Oncology, 2019, 37, 6555-6555.	0.8	2
26	Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinology and Metabolism, 2019, 34, 215.	1.3	68
27	CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 901-909.	0.7	0
28	Employing an oncology decision-support system to quantify treatment variation Journal of Clinical Oncology, 2019, 37, e18067-e18067.	0.8	2
29	Impact of decision-support system and guideline treatment concordance on response rate in advanced lung cancer Journal of Clinical Oncology, 2019, 37, e20006-e20006.	0.8	1
30	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. Thoracic Cancer, 2018, 9, 646-651.	0.8	4
31	Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors. Thoracic Cancer, 2018, 9, 542-547.	0.8	20
32	Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. Nuclear Medicine Communications, 2018, 39, 247-251.	0.5	7
33	NFκB mediated elevation of KCNJ11 promotes tumor progression of hepatocellular carcinoma through interaction of lactate dehydrogenase A. Biochemical and Biophysical Research Communications, 2018, 495, 246-253.	1.0	19
34	Clinical characteristics of hepatocellular carcinoma patients with normal serum alphaâ€fetoprotein level: A study of 112 consecutive cases. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e336-e340.	0.7	3
35	miR‑142 suppresses proliferation and induces apoptosis of osteosarcoma cells by upregulating Rb. Oncology Letters, 2018, 16, 733-740.	0.8	12
36	Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR‑TKI therapy in metastatic lung adenocarcinoma. Oncology Letters, 2018, 16, 2382-2390.	0.8	8

#	Article	IF	CITATIONS
37	Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncology Letters, 2018, 15, 6857-6864.	0.8	7
38	Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation, 2018, 16, 29.	0.6	32
39	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	4.2	426
40	A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma Journal of Clinical Oncology, 2018, 36, 4077-4077.	0.8	7
41	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	1.3	7
42	A comprehensive genomeâ€wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. Cancer Medicine, 2017, 6, 2932-2941.	1.3	84
43	Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF-κB pathway. Oncology Reports, 2017, 37, 2883-2890.	1.2	30
44	<i>TERT</i> Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2017, 58, 258-265.	2.8	92
45	Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget, 2017, 8, 42252-42261.	0.8	54
46	Unfavorable efficacy to 1311 ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb. Oncotarget, 2017, 8, 97407-97415.	0.8	3
47	Safety and tolerability profile of raltitrexed in Chinese patients with locally advanced or recurrent and metastatic colorectal cancer: A phase IV trial Journal of Clinical Oncology, 2017, 35, 571-571.	0.8	3
48	MicroRNA-199a-3p inhibits tumorigenesis of hepatocellular carcinoma cells by targeting ZHX1/PUMA signal. American Journal of Translational Research (discontinued), 2017, 9, 2457-2465.	0.0	21
49	Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1034-1039.	3.3	18
50	Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1307-1313.	1.8	36
51	Serum thyrotropin level of 30ÂμIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer. Endocrine, 2016, 53, 166-173.	1.1	9
52	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	0.4	46
53	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chinese Clinical Oncology, 2016, 5, 12.	0.4	8
54	Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data. Tumor Biology, 2015, 36, 6391-6399.	0.8	23

#	Article	IF	CITATIONS
55	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Annals of Translational Medicine, 2015, 3, 279.	0.7	13
56	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of Translational Medicine, 2015, 3, 322.	0.7	32
57	Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study. Oncologist, 2014, 19, 1169-1178.	1.9	71
58	BRAFV600E Mutation Associated With Non–Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid Carcinoma. Clinical Nuclear Medicine, 2014, 39, 675-679.	0.7	52
59	Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research. 2012. 24, 291-298.	0.7	13
60	Polymorphisms of ERCC1, XPD, XRCC1 and XPG predict clinical outcome in advanced gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Clinical Oncology and Cancer Research, 2009, 6, 328-336.	0.1	0
61	In vitro anti— irradiation effects of a polypeptide from Chlamys farreri. Chinese Journal of Clinical Oncology, 2005, 2, 473-479.	0.0	0